SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2023
Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Comparison of ICS dose reduction vs. montelukast discontinuation for step-down therapy in well-controlled asthma: a pilot randomized controlled trial.BMC pulmonary medicine · 2025Trial
- [Sleep disorders associated with montelukast in children with respiratory allergy].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Changes in the Use of Montelukast for Asthma After a US Food and Drug Administration Boxed Warning.JAMA network open · 2026Article
- Respiratory drugs and psychiatric adverse events in children and adolescents: a pharmacovigilance study based on the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Alterations in GABAergic Interneurons, Neuroinflammation, and Epigenetics: Potential Targets for Therapeutic Strategies in Schizophrenia.Current neuropharmacology · 2026Article
- Pharmacokinetics, safety and preliminary efficacy study of montelukast in critically ill infants with developing bronchopulmonary dysplasia (PRISM).Contemporary clinical trials communications · 2026Article
- Montelukast Prescription Prevalence and Impact on Clinical Outcomes Among Patients with Asthma: A Cross-Sectional Study in Saudi Arabia.Journal of asthma and allergy · 2026Article
- Type 2 Inflammatory Diseases: The Crossroads of Immunity and Metabolism.Research (Washington, D.C.) · 2026Review
- Montelukast and Delirium Risk During Intensive Care Unit (ICU) Stay: Findings from a Cohort Study.Clinical pharmacology : advances and applications · 2026Article
- Increased Risk of Suicide Attempts Among Adolescents With Food Allergy in the United States.JAACAP open · 2025Article
- Three Decades of Managing Pediatric Obstructive Sleep Apnea Syndrome: What's Old, What's New.Children (Basel, Switzerland) · 2025Review
- Article
- Intranasal Corticosteroids and Oral Montelukast for Paediatric Obstructive Sleep Apnoea: A Systematic Review.Pharmaceutics · 2025Review
- Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children.JAMA pediatrics · 2025Article
- Rhinitis in the Geriatric Population: Epidemiological and Cytological Aspects.Geriatrics (Basel, Switzerland) · 2025Review
- Montelukast reduced docetaxel-induced peripheral neuropathy in rats by altering oxidative stress, histopathological damage, and gene expressions.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Effect of leukotriene receptor antagonist use on the future risk of Parkinson's disease in older patients with asthma.Brain communications · 2025Article
- In Silico identification and modelling of FDA-approved drugs targeting T-type calcium channels.PloS one · 2025Article
- Montelukast: risk of mental disorders vs. efficacy-a meta-analysis.Frontiers in pharmacology · 2025Article
- Montelukast deprescribing in outpatient specialty clinics: A single center cross-sectional study.Exploratory research in clinical and social pharmacy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe United States Food and Drug Administration issued a black box warning on the mental health adverse effects of montelukast in 2020. Age-related effects on the risk of developing specific neuropsychiatric events in montelukast users remain largely unknown.
objectiveTo describe the risk of neuropsychiatric events associated with montelukast in adults and children with asthma.
methodsA systematic search of all studies investigating neuropsychiatric events in montelukast users was performed in PubMed, the Cochrane Library and Embase from inception to 7 September 2022. Animal studies and conference abstracts were excluded.
results59 studies (21 pharmacovigilance studies, four reviews from 172 randomised controlled trials, 20 observational studies, 10 case reports and four case series) evaluating neuropsychiatric events in patients with asthma on montelukast were reviewed. No significant association was shown between montelukast and suicide-related events in six of the observational studies. No association was found for depression as defined by the International Classification of Diseases 10
conclusionMontelukast is not associated with suicide- and depression-related events in asthma patients. Older adults may be particularly susceptible to anxiety and sleeping disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.